MDxHealth SA

MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. It operates through the following geographical segments: United States of America, The Netherlands, Belgium, Spain, Poland, Italy, Rest of EU, and Rest of the World. The firm offers ConfirmMDx, SelectMDx, AssureMDx, InformMDx, SelectMDx, and MonitorMDx. The company was founded by Herman Spolders and Philip S. Devine on January 10, 2003 and is headquartered in Herstal, Belgium.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MDxHealth reports strong Q2 revenue growth and operational improvements

MDxHealth's Q2 2024 performance reflects robust revenue growth, driven by increased test volumes and improved margins.
The company's strategic focus on revenue drivers and operational efficiency has led to a reduction in operating losses.
While facing challenges in a competitive market, MDxHealth is well-positioned to capitalize on growth opportunities and deliver strong results.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. It operates through the following geographical segments: United States of America, Europe and Rest of the World. The firm offers ConfirmMDx, SelectMDx, AssureMDx, InformMDx, SelectMDx, and MonitorMDx. The company was founded by Herman Spolders and Philip S. Devine on January 10, 2003 and is headquartered in Herstal, Belgium.

NEWS RELEASE 25 OCTOBER 2023, 4PM ET / 22:00 CET MDxHealth to Present Third Quarter 2023 Financial Results and Corporate Update on November 8 Company to Host Conference Call with Live Q&A, November 8, 2023 at 4:30pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – October 25, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the third quarter and nine-month period ended September 30, 2023, after market close on Wednesday, November 8, 2023. Title: MDxHealth Presents Third Quarter 2023 Financial Results and Corporate Update Conference Call and Webcast Speakers: Michael K.

MDxHealth to Present Third Quarter 2023 Financial Results and Corporate Update on November 8

NEWS RELEASE - REGULATED INFORMATION October 20, 2023 , 4:00 PM EDT / 22:00 CET

Mdxhealth's New Share Capital Amount and New Number of Shares

MDxHealth SA Sponsored ADR (MDXH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MDxHealth SA Sponsored ADR (MDXH) Expected to Beat Earnings Estimates: Should You Buy?

NEWS RELEASE – INSIDE AND REGULATED INFORMATION 9 OCTOBER 2023, 4PM ET / 22:00 CET             MDxHealth Reports Preliminary Q3-2023 Revenues IRVINE, CA, and HERSTAL, BELGIUM – October 9, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today reported preliminary third quarter 2023 revenues, units, and cash position. For the third quarter ended September 30, 2023, the Company expects to report revenues of approximately $19.3 million, representing an increase of 73% over the same period last year and 15% versus the prior quarter; excluding GPS, Q3-2023 revenue increased by 45% over Q3-2022.

MDxHealth Reports Preliminary Q3-2023 Revenues

NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION OCTOBER 2, 2023, 4:00pm ET / 22:00 CET

MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting

NEWS RELEASE September 26 , 202 3 , 5 :00PM EDT / 23:00 CET

Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer

MDxHealth SA (OTC:MXDHF) Q2 2023 Earnings Call Transcript August 23, 2023 4:30 PM ET Company Participants Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Dan Brennan - TD Cowen Andrew Brackmann - William Blair Jason Bednar - Piper Sandler Thomas Vranken - KBC Securities Francois Brisebois - Oppenheimer & Co Operator Greetings, and welcome to MDxHealth's 2023 Q2 and Midyear Earnings Call. [Operator Instructions].

MDxHealth SA (MXDHF) Q2 2023 Earnings Call Transcript

MDxHealth SA Sponsored ADR (MDXH) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.70 per share a year ago.

MDxHealth SA Sponsored ADR (MDXH) Reports Q2 Loss, Tops Revenue Estimates

NEWS RELEASE – REGULATED INFORMATION 23 AUGUST 202 3 , 4:00PM EDT / 22:00 CET

MDxHealth Reports Q2 and Half Year 2023 Results

NEWS RELEASE 10 AUGUST 202 3 , 4 PM ET / 22:00 CET

MDxHealth to Present Q2 and Half Year 2023 Financial Results and Corporate Update on August 23

Cigna

Expansion of coverage with Cigna now includes full menu of Company's precision diagnostic prostate cancer tests, representing more than 15 million lives under coverage.

Cigna Expands Commercial and Medicare Advantage Coverage to Include Mdxhealth's Select mdx for Prostate Cancer Test

NEWS RELEASE - REGULATED INFORMATION                 30 June 2023 , 10:00 p.m. CE S T

MDxHealth Announces Results of its Extraordinary General Shareholders' Meeting

NEWS RELEASE – REGULATED INFORMATION JUNE 5 , 2023, 5 :30 pm ET/ 2 3 :30 CE S T MDxHealth Announces its Extraordinary General Shareholders' Meeting IRVINE, CA, and HERSTAL, BELGIUM – June 5, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxh ealth"), a commercial-stage precision diagnostics company, today invites the holders of securities issued by the Company to its extraordinary general shareholders' meeting that will be held on Friday, June 30, 2023 at 9:00 a.m., Belgian time.

MDxHealth Announces its Extraordinary General Shareholders' Meeting

NEWS RELEASE - REGULATED INFORMATION                 25 May 2023 , 22:30 CET

MDxHealth Announces Results of its Annual and Extraordinary General Shareholders' Meetings

NEWS RELEASE May 23 , 2023, 4 PM ET/ 22: 0 0 CET MDxHealth to Present at the 43 rd Annual William Blair Growth Stock Conference IRVINE, CA, and HERSTAL, BELGIUM – May 23, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH), a commercial-stage precision diagnostics company, today announced that Michael McGarrity, Chief Executive Officer, will present at William Blair's 43rd Annual Growth Stock Conference on Thursday, June 8, 2023, at 1:00pm ET. A live webcast of the presentation will be available on the Company's website.

MDxHealth to Present at the 43rd Annual William Blair Growth Stock Conference

MDxHealth SA (OTC:MXDHF) Q1 2023 Earnings Conference Call May 15, 2023 4:30 AM ET Company Participants Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Thomas Vranken - KBC Securities Mark Massaro - BTIG Operator Greetings. Welcome to the MDxHealth First Quarter 2023 Earnings Call.

MDxHealth SA (MXDHF) Q1 2023 Earnings Call Transcript

MDxHealth SA Sponsored ADR (MDXH) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.05 per share a year ago.

MDxHealth SA Sponsored ADR (MDXH) Reports Q1 Loss, Tops Revenue Estimates

NEWS RELEASE - REGULATED INFORMATION 15 MAY 202 3 , 4:00PM EDT / 22:00 CET

MDxHealth Reports Q1-2023 Results

NEWS RELEASE 1 MAY 202 3 , 4PM ET / 22 :00 CET

MDxHealth to Present First Quarter 2023 Financial Results on May 15

NEWS RELEASE – REGULATED INFORMATION APRIL 2 5 , 2023, 4: 00 pm ET/ 22: 00 CET

MDxHealth Announces its Ordinary and Extraordinary General Shareholders' Meetings

MDxHealth SA Sponsored ADR (MDXH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: MDxHealth SA Sponsored ADR (MDXH) Q1 Earnings Expected to Decline

IRVINE, CA, and HERSTAL, BELGIUM – April 7, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act"), that it received the following notification.

MDxHealth Shareholder Transparency Declaration

MDxHealth has 4 validated testing products with one more in the clinical pipeline. All are focused specifically on urology. The company expects to do ~$65-$70M of sales in 2023, but the valuation is a paltry $88M.

MDxHealth: Who Doesn't Love A Good Prostate Exam?

IRVINE, CA, and HERSTAL, BELGIUM – March 13, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today confirms that neither MDxHealth SA, nor any of its subsidiaries, have any exposure to Silicon Valley Bank (“SVB”) or Silvergate Bank.

MDxHealth Confirms No Exposure to Silicon Valley Bank or Silvergate Bank

MDxHealth SA (OTCPK:MXDHF) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Francois Brisebois - Oppenheimer Mark Massaro - BTIG Thomas Franken - KBC Securities Operator Greetings. Welcome to the MDxHealth Fourth Quarter and Full Year 2022 Earnings Call.

News for MDxHealth SA Stock (MDXH)